Ulrich‐Peter Rohr

1.8k total citations
25 papers, 1.2k citations indexed

About

Ulrich‐Peter Rohr is a scholar working on Oncology, Molecular Biology and Hematology. According to data from OpenAlex, Ulrich‐Peter Rohr has authored 25 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 6 papers in Molecular Biology and 6 papers in Hematology. Recurrent topics in Ulrich‐Peter Rohr's work include Cancer Treatment and Pharmacology (5 papers), Neuroendocrine Tumor Research Advances (4 papers) and Multiple Myeloma Research and Treatments (4 papers). Ulrich‐Peter Rohr is often cited by papers focused on Cancer Treatment and Pharmacology (5 papers), Neuroendocrine Tumor Research Advances (4 papers) and Multiple Myeloma Research and Treatments (4 papers). Ulrich‐Peter Rohr collaborates with scholars based in Germany, United States and Switzerland. Ulrich‐Peter Rohr's co-authors include Leonard B. Saltz, Herbert I. Hurwitz, Ralf Kronenwett, Rainer Haas, James T. Cassidy, Roland Fenk, Peter G. Compton, Jane Huang, Benjamin Besse and Bruce J. Giantonio and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Annals of Internal Medicine.

In The Last Decade

Ulrich‐Peter Rohr

25 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ulrich‐Peter Rohr Germany 15 513 296 285 224 135 25 1.2k
Gisela Schwab United States 13 644 1.3× 352 1.2× 361 1.3× 86 0.4× 135 1.0× 23 1.3k
Monica Giordano Italy 22 690 1.3× 205 0.7× 443 1.6× 300 1.3× 105 0.8× 93 1.6k
Jacques Camerlo France 18 448 0.9× 162 0.5× 172 0.6× 212 0.9× 105 0.8× 50 932
Giuseppe Fornarini Italy 22 597 1.2× 562 1.9× 245 0.9× 165 0.7× 101 0.7× 125 1.3k
Cédric Rossi France 21 355 0.7× 262 0.9× 197 0.7× 209 0.9× 214 1.6× 77 1.3k
Yan Song United States 20 613 1.2× 435 1.5× 419 1.5× 126 0.6× 62 0.5× 132 1.5k
Mark Shapiro United States 21 471 0.9× 537 1.8× 157 0.6× 351 1.6× 317 2.3× 49 1.4k
S.L. Tucker United States 19 559 1.1× 420 1.4× 218 0.8× 155 0.7× 235 1.7× 39 1.4k
Cosimo Sacco Italy 18 527 1.0× 389 1.3× 276 1.0× 54 0.2× 155 1.1× 59 1.2k
Evangelia Razis Greece 23 1.0k 2.0× 417 1.4× 412 1.4× 64 0.3× 164 1.2× 77 1.6k

Countries citing papers authored by Ulrich‐Peter Rohr

Since Specialization
Citations

This map shows the geographic impact of Ulrich‐Peter Rohr's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ulrich‐Peter Rohr with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ulrich‐Peter Rohr more than expected).

Fields of papers citing papers by Ulrich‐Peter Rohr

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ulrich‐Peter Rohr. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ulrich‐Peter Rohr. The network helps show where Ulrich‐Peter Rohr may publish in the future.

Co-authorship network of co-authors of Ulrich‐Peter Rohr

This figure shows the co-authorship network connecting the top 25 collaborators of Ulrich‐Peter Rohr. A scholar is included among the top collaborators of Ulrich‐Peter Rohr based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ulrich‐Peter Rohr. Ulrich‐Peter Rohr is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Vokinger, Kerstin Noëlle, et al.. (2023). Regulatory Review Duration and Differences in Submission Times of Drugs in the United States and Europe, 2011 to 2020. Annals of Internal Medicine. 176(10). 1413–1418. 9 indexed citations
3.
Pavic, Matea, Anita Wolfer, Qiyu Li, et al.. (2023). Regulatory Challenges: Is a Surrogate End Point Instead of Overall Survival Enough for Regulatory Approval of (Neo)Adjuvant Cancer Treatment? The Swissmedic Perspective. Journal of Clinical Oncology. 41(32). 4973–4975. 3 indexed citations
4.
Vellanki, Paz J., Nicole Drezner, Xiaoxue Li, et al.. (2021). FDA Approval Summary: Osimertinib for Adjuvant Treatment of Surgically Resected Non–Small Cell Lung Cancer, a Collaborative Project Orbis Review. Clinical Cancer Research. 27(24). 6638–6643. 42 indexed citations
5.
Rohr, Ulrich‐Peter, et al.. (2016). The Value of In Vitro Diagnostic Testing in Medical Practice: A Status Report. PLoS ONE. 11(3). e0149856–e0149856. 136 indexed citations
6.
Vyberg, Mogens, Søren Nielsen, Rasmus Røge, et al.. (2015). Immunohistochemical expression of HER2 in breast cancer: socioeconomic impact of inaccurate tests. BMC Health Services Research. 15(1). 352–352. 16 indexed citations
7.
Cassidy, James T., Leonard B. Saltz, Bruce J. Giantonio, et al.. (2009). Effect of bevacizumab in older patients with metastatic colorectal cancer: pooled analysis of four randomized studies. Journal of Cancer Research and Clinical Oncology. 136(5). 737–743. 118 indexed citations
8.
Rohr, Ulrich‐Peter, et al.. (2009). Safety of bevacizumab in patients with metastases to the central nervous system. Journal of Clinical Oncology. 27(15_suppl). 2007–2007. 8 indexed citations
9.
Rohrbeck, Astrid, Judith Neukirchen, Helene Geddert, et al.. (2008). Gene expression profiling for molecular distinction and characterization of laser captured primary lung cancers. Journal of Translational Medicine. 6(1). 69–69. 56 indexed citations
10.
Geddert, Helene, Astrid Rohrbeck, Guillermo García, et al.. (2006). The influence of the pituitary tumor transforming gene-1 (PTTG-1) on survival of patients with small cell lung cancer and non-small cell lung cancer.. Journal of Carcinogenesis. 5(1). 4–4. 29 indexed citations
11.
Papewalis, Claudia, Martin Faßnacht, Holger S. Willenberg, et al.. (2006). Dendritic cells as potential adjuvant for immunotherapy in adrenocortical carcinoma. Clinical Endocrinology. 65(2). 215–222. 21 indexed citations
12.
Fenk, Roland, Mark Michael, Fabian Zohren, et al.. (2006). Escalation Treatment Algorithm with Bortezomib, Dexamethasone and Bendamustine for Patients with Relapsed or Refractory Multiple Myeloma: A Singel Centre Experience.. Blood. 108(11). 3540–3540. 1 indexed citations
13.
Geddert, Helene, Helmut E. Gabbert, Ulrich Steidl, et al.. (2006). Coexpression of Fragile Histidine Triad and c-kit Is Relevant for Prediction of Survival in Patients with Small Cell Lung Cancer. Cancer Epidemiology Biomarkers & Prevention. 15(11). 2232–2238. 5 indexed citations
14.
Rohr, Ulrich‐Peter, Helene Geddert, Ingmar Bruns, et al.. (2005). Prognostic Relevance of Fragile Histidine Triad Protein Expression in Patients with Small Cell Lung Cancer. Clinical Cancer Research. 11(1). 180–185. 10 indexed citations
15.
16.
Rohr, Ulrich‐Peter, Helene Geddert, Wolfram Müller, et al.. (2004). Expression of the tyrosine kinase c‐kit is an independent prognostic factor in patients with small cell lung cancer. International Journal of Cancer. 111(2). 259–263. 35 indexed citations
17.
Fenk, Roland, Guido Kobbe, Ulrich Steidl, et al.. (2004). Levels of minimal residual disease detected by quantitative molecular monitoring herald relapse in patients with multiple myeloma.. PubMed. 89(5). 557–66. 28 indexed citations
18.
Kronenwett, Ralf, Thorsten Gräf, Markus Weber, et al.. (2002). Inhibition of angiogenesis in vitro by αv integrin–directed antisense oligonucleotides. Cancer Gene Therapy. 9(7). 587–596. 19 indexed citations
19.
Steidl, Ulrich, Ralf Kronenwett, Ulrich‐Peter Rohr, et al.. (2002). Gene expression profiling identifies significant differences between the molecular phenotypes of bone marrow–derived and circulating human CD34+ hematopoietic stem cells. Blood. 99(6). 2037–2044. 118 indexed citations
20.
Kobbe, Guido, Philipp Schneider, Ulrich‐Peter Rohr, et al.. (2001). Treatment of severe steroid refractory acute graft-versus-host disease with infliximab, a chimeric human/mouse antiTNFα antibody. Bone Marrow Transplantation. 28(1). 47–49. 110 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Gisela Schwab Breakdown of academic impact, for papers by Monica Giordano Breakdown of academic impact, for papers by Jacques Camerlo Breakdown of academic impact, for papers by Giuseppe Fornarini Breakdown of academic impact, for papers by Cédric Rossi Breakdown of academic impact, for papers by Yan Song Breakdown of academic impact, for papers by Mark Shapiro Breakdown of academic impact, for papers by S.L. Tucker Breakdown of academic impact, for papers by Cosimo Sacco Breakdown of academic impact, for papers by Evangelia Razis
Rankless by CCL
2026